-
Clinical trial to test new immunotherapy for multiple myeloma
-
Moxetumomab pasudotox becomes first FDA-approved drug for resistant hairy cell leukemia
-
Bacteria could promote lung cancer progression and be biomarkers for the disease
-
Our leukemia and lymphoma research
-
Clinical trial tests immunotherapy combination for lung cancer
-
RT @NCICCR_VB: Dr. Arlene Sharpe @harvardmed @BrighamWomens presents @NCIResearchCtr Eminent Lecture “The Multifaceted Functions… https://t.co/M7P0q3Dqvk
-
RT @NCIEpiTraining: DCEG study forecasts an increase in #ProstateCancer through 2025, especially in men younger than 69 years of age.… https://t.co/qbrtq3aivs
-
RT @theNCI: "This is, without a doubt, a time of great hope in cancer research," writes @NCIDirector Dr. Ned Sharpless on… https://t.co/7I59Ckovha
-
RT @theNCI: Today, the National Cancer Institute released its Annual Plan and Budget Proposal for fiscal year 2020:… https://t.co/eTvO6CEZAJ
-
Interested in a career in #cancerresearch? Application deadline is September 30th for the Clinical Investigator Dev… https://t.co/LD3ivrDWUk
-
Hundreds of trainees come from across the globe to experience our world-class training environment… https://t.co/yqilwREtLn
-
#BloodCancerAwarenessMonth Learn about #lymphoma research and clinical trials available through our @NCICCR_Lymphoma https://t.co/OR6pVQ7VPl
